These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34453222)

  • 21. Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia.
    Corpeleijn WE; de Waal WJ; Schipper HS; Wiegman A
    Diabetologia; 2024 Jan; 67(1):19-26. PubMed ID: 38032368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L
    Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reverse Cascade Screening for Familial Hypercholesterolemia.
    Vinson A; Guerra L; Hamilton L; Wilson DP; Fnla
    J Pediatr Nurs; 2019; 44():50-55. PubMed ID: 30683281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents.
    Tada H; Takamura M; Kawashiri MA
    Vasc Health Risk Manag; 2021; 17():59-67. PubMed ID: 33628029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review.
    Masson W; Corral P; Barbagelata L; Lavalle-Cobo A; Nogueira JP; Siniawski D; Ray KK
    J Clin Lipidol; 2022; 16(5):562-573. PubMed ID: 35918256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial hypercholesterolemia care by Dutch pediatricians-mind the gaps.
    van den Bosch SE; Hutten BA; Ibrahim S; Wiegman A; Pang J; Watts GF; Corpeleijn WE
    Eur J Pediatr; 2024 Sep; 183(9):3877-3883. PubMed ID: 38888644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Duell PB; Gidding SS; Andersen RL; Knickelbine T; Anderson L; Gianos E; Shrader P; Kindt I; O'Brien EC; McCann D; Hemphill LC; Ahmed CD; Martin SS; Larry JA; Ahmad ZS; Kullo IJ; Underberg JA; Guyton J; Thompson P; Wilemon K; Roe MT; Rader DJ; Cuchel M; Linton MF; Shapiro MD; Moriarty PM; Knowles JW
    Atherosclerosis; 2019 Oct; 289():85-93. PubMed ID: 31487564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cascade screening of familial hypercholesterolemia must go on.
    Galema-Boers JM; Versmissen J; Roeters van Lennep HW; Dusault-Wijkstra JE; Williams M; Roeters van Lennep JE
    Atherosclerosis; 2015 Oct; 242(2):415-7. PubMed ID: 26282946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Coutinho ER; Miname MH; Rocha VZ; Bittencourt MS; Jannes CE; Tada MT; Lima IR; Filho WS; Chacra AP; Pereira AC; Krieger JE; Santos RD
    Atherosclerosis; 2021 Feb; 318():32-37. PubMed ID: 33450476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members.
    Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL
    J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Screening for familial hypercholesterolemia from low-density lipoprotein cholesterol levels at admission in the coronary care unit].
    Chemaly P; Nallet O; Delarche N; Legagneur C; Boulestreau R; Reibel I; Palette C; Grenier A; Courtade H; Beaune G; Belle L; Georges JL
    Ann Cardiol Angeiol (Paris); 2018 Nov; 67(5):300-309. PubMed ID: 30290906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Statins in Children and Adolescents With Familial Hypercholesterolemia: A Systematic Review.
    Dombalis S; Nash A
    J Pediatr Health Care; 2021; 35(3):292-303. PubMed ID: 33342622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric heterozygous familial hypercholesterolemia patients have locally increased aortic pulse wave velocity and wall thickness at the aortic root.
    Tran A; Burkhardt B; Tandon A; Blumenschein S; van Engelen A; Cecelja M; Zhang S; Uribe S; Mura J; Greil G; Hussain T
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1903-1911. PubMed ID: 31209684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving the detection of familial hypercholesterolaemia.
    Lan NSR; Martin AC; Brett T; Watts GF; Bell DA
    Pathology; 2019 Feb; 51(2):213-221. PubMed ID: 30579649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.